挽救性使用安罗替尼在经大量前期治疗的表皮生长因子受体（EGFR）野生型肺腺癌中显示出持续疗效：一例病例报告及文献综述
Salvage anlotinib showed sustained efficacy in heavily pretreated EGFR wild-type lung adenocarcinoma: A case report and review of the literature.
作者信息
Liu Lei, Wang Xiang, Wu Wen-Bin, Zhang Miao
机构信息
Institute of Digestive Disease, China Three Gorges University, Department of Gastroenterology of Yichang Central People's Hospital, Yichang, China.
Department of Thoracic Surgery, Xuzhou Central Hospital, Xuzhou, China.
出版信息
Medicine (Baltimore). 2020 Oct 9;99(41):e22707. doi: 10.1097/MD.0000000000022707.
RATIONALE
Anlotinib has been proved to be effective in advanced refractory non-small cell lung cancer.
PATIENT CONCERNS
A 47-year-old female non-smoker was admitted due to persistent chest tightness for a month.
DIAGNOSES
Epidermal growth factor receptor (EGFR) wild-type advanced primary lung adenocarcinoma without brain or bone metastasis.
INTERVENTIONS
The patient failed 2 lines of pemetrexed/docetaxel plus carboplatin and third-line erlotinib. Fourth-line anlotinib was administered thereafter.
OUTCOMES
The pulmonary lesions showed partial remission 5 months after anlotinib monotherapy. The patient demonstrated a progression-free survival of more than 7 months and an overall survival of >12 months. The adverse events including hypertension and fatigue were well-tolerated.
LESSONS
Salvage anlotinib might be a reasonable choice in EGFR wild-type lung adenocarcinoma after failure of chemotherapy. Further well-designed trials are warranted to verify this occasional finding.
理论依据
安罗替尼已被证明对晚期难治性非小细胞肺癌有效。
患者情况
一名47岁不吸烟女性因持续胸闷1个月入院。
诊断
表皮生长因子受体（EGFR）野生型晚期原发性肺腺癌，无脑或骨转移。
干预措施
患者接受培美曲塞/多西他赛联合卡铂一线治疗及二线厄洛替尼治疗均失败，此后接受四线安罗替尼治疗。
结果
安罗替尼单药治疗5个月后肺部病变部分缓解。患者无进展生存期超过7个月，总生存期>12个月。包括高血压和疲劳在内的不良事件耐受性良好。
经验教训
在化疗失败的EGFR野生型肺腺癌中，挽救性使用安罗替尼可能是一个合理选择。有必要开展进一步设计良好的试验来验证这一偶然发现。
Zotero 插件